B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 report. The firm says Ionis Pharmaceuticals’ (IONS) Tryngolza early launch trends to offer visibility into Arrowhead’s near-term commercial prospects.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals: Promising Pipeline Amidst Cautious Financial Outlook Warrants Hold Rating
- Arrowhead Pharmaceuticals: Promising Drug Approval and Expanding Pipeline Justify Buy Rating
- Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Arrowhead Pharmaceuticals: Promising Pipeline and Strategic Developments Drive Buy Rating
- Arrowhead Pharmaceuticals Reports Q1 2025 Financial Results